MedTrace Logo

CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer

NCT05795335 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 172

Last updated 2023-05-16

No results posted yet for this study

Summary

This is an ambispective, single-center study to evaluate the survival outcomes, adverse events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer.

Conditions

Interventions

DRUG

CDK4/6 inhibitor

CDK4/6 inhibitors

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2026-04-30
Completion
2028-12-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05795335 on ClinicalTrials.gov